Patents by Inventor Estelle Trifilieff

Estelle Trifilieff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS
    Publication number: 20220340668
    Abstract: The present disclosure provides an ActRII antagonist, e.g., the ActRIIA and/or ActRIIB antagonist, e.g., an anti-ActRII receptor antibody or antigen-binding fragment thereof, e.g., bimagrumab, for treating or preventing liver disease or disorder in a subject in need thereof. The present disclosure also relates to pharmaceutical combinations comprising such ActRII antagonists and at least one further therapeutic agent in the treatment or prevention of liver disease or disorder.
    Type: Application
    Filed: September 1, 2020
    Publication date: October 27, 2022
    Inventors: Laura COLEMAN, C. Daniel MEYERS, Ronenn ROUBENOFF, Estelle TRIFILIEFF
  • USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF
    Publication number: 20220265823
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment Especially, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: Shinji HATAKEYAMA, Ronenn ROUBENOFF, Estelle TRIFILIEFF, Jerome FEIGE, Lloyd B. KLICKSTEIN
  • Uses of myostatin antagonists, combinations containing them and uses thereof
    Patent number: 11357851
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Shinji Hatakeyama, Ronenn Roubenoff, Estelle Trifilieff, Jerome Feige, Lloyd B. Klickstein
  • METHODS FOR PREVENTING AND TREATING URINARY INCONTINENCE
    Publication number: 20200181271
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating urinary incontinence, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: June 26, 2018
    Publication date: June 11, 2020
    Inventors: Shinji HATAKEYAMA, Michaela KNEISSEL, Estelle TRIFILIEFF
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20180194846
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 12, 2018
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20180134791
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: July 23, 2015
    Publication date: May 17, 2018
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA
    Publication number: 20170260275
    Abstract: The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.
    Type: Application
    Filed: December 4, 2015
    Publication date: September 14, 2017
    Inventors: Patrick KORTEBEIN, Daniel ROOKS, Lloyd B. KLICKSTEIN, Ronenn ROUBENOFF, David GLASS, Estelle TRIFILIEFF, Dimitris PAPANICOLAOU
  • Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
    Patent number: 9365651
    Abstract: The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: June 14, 2016
    Assignee: Novartis AG
    Inventors: Jerome Feige, David Glass, Shinji Hatakeyama, Brian Peter Richardson, Estelle Trifilieff
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20160031993
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: July 23, 2015
    Publication date: February 4, 2016
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • Method for Treating Metabolic Disorders
    Publication number: 20140328848
    Abstract: The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters.
    Type: Application
    Filed: June 29, 2012
    Publication date: November 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Jerome Feige, David Glass, Shinji Hatakeyama, Brian Peter Richardson, Estelle Trifilieff
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20130344091
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: August 29, 2013
    Publication date: December 26, 2013
    Applicant: Novartis AG
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • Compositions and methods for increasing muscle growth
    Patent number: 8551482
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: October 8, 2013
    Assignee: Novartis AG
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stephanie Urlinger
  • Compositions and methods for increasing muscle growth
    Patent number: 8388968
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: March 5, 2013
    Assignee: Novartis AG
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stefanie Urlinger
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20120237521
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 20, 2012
    Applicant: NOVARTIS AG
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle Trifilieff, Stefanie Urlinger
  • COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
    Publication number: 20100272734
    Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 28, 2010
    Inventors: Catrin Berger, Tanja Herrmann, Chris Lu, Kelly-Ann Sheppard, Estelle TRIFILIEFF, Stefanie Urlinger